Liquid Crystal Lipid Pre-Concentrate for Sustained GnRH Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional sustained-release formulations for GnRH analogues, such as PLGA microparticles and Eligard, face challenges including complex fabrication processes, low drug stability, high initial burst concentrations, pain, inflammation, and instability at room temperature, which affect their efficacy and usability.
Innovation Solution
A pharmaceutical composition comprising sorbitan unsaturated fatty acid ester, phospholipid, liquid crystal hardener, and a GnRH analogue that forms a liquid crystal phase upon exposure to aqueous fluids, enhancing sustained release and biodegradability, and allowing for safe and effective injection without pain or inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If PLGA microparticles are used for sustained release, then the effective concentration can be maintained for a specific period, but the fabrication process becomes complicated and drug loading efficiency is poor
Solution Approach 1:
The patent changes the physical-chemical parameters of the carrier system from solid PLGA microparticles to liquid crystalline lipid composition. This parameter change simplifies the fabrication process while maintaining sustained release capability, as the liquid crystal formulation can be directly injected without complex microparticle fabrication steps.
Solution Approach 2:
The patent uses a composite lipid formulation consisting of multiple components (phospholipids, cholesterol, free fatty acids) that self-assemble into liquid crystalline structures. This composite material approach provides both sustained release functionality and simplified processing compared to PLGA microparticles.
2Duration of action of moving object
If PLGA microparticles are used for sustained release, then the effective concentration can be maintained, but the sterilization process becomes difficult and requires highly sterile conditions
Solution Approach 1:
The patent changes the physical state from solid microparticles to liquid crystalline phase, which allows for easier sterilization. The liquid crystal formulation can be sterilized by filtration or autoclavage without compromising the sustained release mechanism, unlike PLGA microparticles that require highly sterile conditions during fabrication.
3Duration of action of moving object
If PLGA microparticles are used for sustained release, then the effective concentration can be maintained, but acetic acid impurities induce inflammation and reduce cell growth rates
Solution Approach 1:
The patent eliminates the harmful acetic acid impurities inherent in PLGA degradation by using a lipid-based liquid crystal system. The lipid components naturally degrade into non-inflammatory products (fatty acids, glycerol, phosphate), converting the harmful degradation pathway into a beneficial one that avoids tissue inflammation while maintaining sustained release.
Solution Approach 2:
The patent uses biocompatible, biodegradable lipid materials that naturally break down into harmless products. This approach replaces the problematic PLGA system with materials that are inherently safer for tissue, even though the degradation products differ chemically.
4Duration of action of moving object
If a suspension of PLGA microparticles is injected for sustained release, then the effective concentration can be maintained, but pain and tissue damage occur at the injection site
Solution Approach 1:
The patent changes the formulation from solid microparticle suspension to liquid crystalline phase. This parameter change allows the formulation to be injected in a liquid state that is less traumatic to tissue, reducing injection site pain and damage while still providing sustained release through the liquid crystal-to-aqueous environment transition in vivo.
5Ease of operation
If Eligard formulation is used, then the usability is improved compared to PLGA microparticles, but the product exhibits high initial burst concentration which is undesirable
Solution Approach 1:
The patent optimizes the lipid composition and liquid crystal structure to control drug release kinetics. By adjusting parameters such as lipid chain length, saturation, and liquid crystal phase properties, the formulation achieves both ease of injection and controlled release that minimizes initial burst while maintaining sustained release over time.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves stable and prolonged release of GnRH analogues with reduced initial burst concentrations, improved biodegradability, and enhanced safety, maintaining effective plasma concentrations for extended periods without the side effects associated with conventional formulations.
Implementation Method 1
A pharmaceutical composition comprising sorbitan unsaturated fatty acid ester, phospholipid, liquid crystal hardener, and a GnRH analogue that forms a liquid crystal phase upon exposure to aqueous fluids
Implementation Method 2
enhancing sustained release and biodegradability
Data Source
AI summary
Disclosed is a pharmaceutical composition, comprising: a) at least one sorbitan unsaturated fatty acid ester having a polar head with at least two or more —OH (hydroxyl) groups; b) at least one phospholipid; c) at least one liquid crystal hardener which is free of an ionizable group and has a triacyl group with 15 to 40 carbon atoms or a carbon ring structure in a hydrophobic moiety; and d) at least one GnRH (gonadotropin-releasing hormone) analogue as a pharmacologically active substance, wherein said lipid pre-concentrate exists as a liquid phase in absence of aqueous fluid and forms into a liquid crystal in presence of aqueous fluid. The pharmaceutical composition is configured to enhance the sustained release of the pharmacologically active substance GnRH analogue.